compani
messag beat revenu ep vs consensu
vs consensu revenu growth yoy driven pharma
volum diabet volum growth increas ep guidanc
base expect higher oper incom lower effect
tax rate revenu guidanc also increas
base expect lower rebat discount lower medicaid util
favor payer mix fx impact one import clinic read-out come
rewind trulic
new pharma product trulic taltz jardianc contribut ww
pharma growth growth recent expir sever product includ effient
strattera zyprexa contribut
call manag state baricitinib approv countri
dose mg mg major use high mg dose new safeti
signal observ real world set account patient year
data intend get dose approv fda despit advisori panel
recommend mg dose see note yesterday furthermor dose still
evalu clinic trial atop dermat
top line result rewind studi expect detail result follow
medic meet lli focu remain larg diabet franchis evidenc
trulic expect novo nordisk nvo ozemp anoth once-weekli
receptor agonist provid competit trulic demonstr
differ label howev ozemp data sustain
show increas risk mace ozemp novo price strategi might key
want prevail crowd diabet space believ novo roughli one
year less unperturb launch readout trulic cv outcom
studi rewind late outcom rewind crucial trulic growth
potenti rewind illustr posit benefit reduc major cardiovascular
event person type diabet like estim trulic would
increas beyond neg read-out would perhap leav trulic par
similar agent price could ultim agent drive demand note
sustain ozemp trial patient percentag cardiovascular
mace event lower compar placebo group deem
noninferior therebi ozemp found caus cv event durat
studi week week dose week follow-up lilli rewind
trial larger much longer durat year averag
durat follow-up base size durat rewind believ
good likelihood success
oncolog see growth alimta due posit ph result mrk
new migrain drug galcanezumab see deep dive express script
esrx press forego usual price strategi high list price hefti rebat
also seek refund drug dont work within defin time-frame manag
think galcanezumab differenti among compound class
base higher efficaci rapid effect approv anticip year
page analyst certif import disclosur
made adjust model base result updat guidanc
manag commentari compani earn call increas revenu
estim result better expect pharmaceut growth first quarter
continu model non-gaap gross margin approxim decreas
estim tax rate fy due updat tax rate guidanc provid
morn year model compound-annual-growth-rate continu
expect strong growth strong uptak new product addit
slightli taken baricitinib estim remain unclear whether
receiv approv dose adjust revenu estim
increas respect ep
estim increas
primarili driven decreas tax rate
valuat risk
valuat reiter price target use dcf analysi
use long-term growth rate unchang wacc calcul use
risk-fre rate equiti risk premium maintain buy rate
base approv abemaciclib expect abemaciclib approv front
line set uptak recent launch product taltz trulic jardianc go
forward strong expect growth class diabet drug
improv oper effici futur year
risk risk rate estim pt includ higher-than-anticip oper
expens new product launch may poorli expect higher
expens lower revenu may lead lower profit manag care could
push back rel price new brand product may affect assumpt
futur revenu final area includ diabet oncolog much
competit may slow initi demand new product
page analyst certif import disclosur
million except per-shar figur
adjust dilut ep excl amort intang
page analyst certif import disclosur
